News

Phase I trial of CPI-0610 in myeloma commences

The US company, Constellation Pharmaceuticals, has announced that it has initiated a new Phase I trial of its proprietary drug, CPI-0610, for the treatment of myeloma patients who have relapsed after at least one prior line of treatment. CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins which are involved in chromatin…

Details

Velcade retreatment approved for myeloma patients

The US Food and Drug Administration (FDA) has approved the use of Velcade for the retreatment of myeloma patients who have previously responded to Velcade treatment and relapsed at least six months following completion of prior Velcade treatment. The approval is based on the results of the Phase II RETRIEVE trial which showed an overall…

Details

Phase III trial of Kyprolis® for myeloma patients meets primary endpoint

Amgen, the US biopharmaceutical company and its subsidiary, Onyx Pharmaceuticals, have announced that interim analysis of their Phase III clinical trial ASPIRE for relapsed myeloma patients has met the primary endpoint of progression-free survival. The results showed that patients treated with Kyprolis (carfilzomib) in combination with Revlimid and dexamethasone demonstrated significantly longer progression-free survival (median 26.3…

Details

NICE issue new draft ‘no’ for Revlimid® at first relapse

The National Institute for Health and Care Excellence (NICE) has issued a second draft guidance not recommending the use of Revlimid for myeloma patients at first relapse who have previously received Velcade® and who are not eligible for high-dose therapy and autologous stem cell transplantation. The appraisal consultation document has outlined that Revlimid is not considered…

Details

Study identifies drug that may help myeloma patients with thrombocytopenia

A study has identified a previously unknown but crucial component of platelet production that could help prevent Velcade-induced thrombocytopenia in myeloma patients. The researchers found that proteasome inhibition blocked proplatelet formation in megakaryocytes via upregulation and hyperactivation of the small GTPase, RhoA. Inhibition of the RhoA pathway with fasudil, a drug used to treat cerebral…

Details

Binding Site to support the International Myeloma Foundation’s Black Swan Research Initiative®

Binding Site, the UK clinical diagnostic company, has announced that it will be collaborating with the US-based International Myeloma Foundation (IMF) on its Black Swan Research Initiative. Binding Site’s Freelite® and Hevylite® tests, two unique blood tests for measuring serum free light chains and intact monoclonal heavy chains respectively, will form part of the toolkit…

Details

New frontline daratumumab trial for myeloma to commence

Genmab, the Danish biotechnology company, has announced that it’s partner Janssen Biotech Inc. will be starting a new Phase III trial of daratumumab as a frontline treatment for myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplantation. Daratumumab is an anti-CD38 monoclonal antibody with promising anti-myeloma activity that is currently being…

Details

Improvement in survival rates for haematological malignancies in Europe

The Eurocare-5 study, a population-based registry study of cancer survival across Europe, has found significant improvements in the five-year survival rates for haematological malignancies between 1997 and 2008. The results, published online in the Lancet Oncology, showed for example that amongst myeloma patients the five-year survival rate increased from 29.8% to 39.6%. These gains coincided with the introduction…

Details